The TNF receptor associated periodic syndrome is a periodic fever syndrome which often remains connected with mutations in a receptor for the molecule tumor necrosis factor. It is also inheritable in the autosomal dominant ways. Several individuals having the TRAPS develop some episodic symptoms like rash, recurrent high fevers, joint/muscle aches and abdominal pain.
The TNF is often developed from the cells in the immune system which is also referred as macrophages. The macrophages produces in response to the infection and other stimuli. The TNF receptor associated periodic syndrome helps in activating many other immune cells playing a major role in the initiation of the inflammation. The patients having TRAPS develop change in the tumor necrosis factor receptor-1 (TNFR1) gene. It is a mechanism in which alterations that develop in the TNFR1 lead to the TRAPS phenotype have been kept under investigation still.
Several treatment processes have been developed to treat the TNF receptor associated periodic syndrome. The common medication forms include etanercept, infliximab, and tacrolimus. However still no single drug has been investigated that can treat all the cases of TRAPS. The TRAPS was first recognized in the year 1982 in a boy of Scottish-Irish origin. During those days the TRAPS was named as Hibernian fever.
The hereditary periodic fever syndrome is defined as frequent attacks of the generalized inflammation. For this disease no infectious or self-immune cause has been identified. Several clinical variations, unique biochemical precise irregularity and the genetic mode inheritance differentiate the four main diseases. These four diseases include familial Mediterranean fever, TNF-receptor-associated periodic syndrome, hyper-immunoglobulinemia D, and Muckle Wells syndrome have been recognized. The disease occurs with some prolonged fever attacks and severe irritation and swelling. It also results into having the serum levels of soluble TNF-receptor causing the inflammation with some unopposed TNF-alpha action.The common treatment process of diagnosing TNF receptor associated periodic syndrome is the Corticosteroid which is again not always effective in most of the TRAPS patients.
|
|
Different surveys have been done to recognize the severity of the TNF receptor associated periodic syndrome. According to the present report, the TNF extends the clinical and genetic spectrum of autoinflammatory disorder, tumor necrosis factor and the receptor-associated periodic syndrome.
Medical laboratories all over the world at present are undertaking both the clinical and basic research studies for making clear the role of the mutations in several common inflammatory diseases.
To know more about the TNF receptor associated periodic syndrome browse to our web site arthritisxl.com
|
